Matinas BioPharma Holdings Inc. (AMEX:MTNB) finished Thursday with a subtraction of -$0.14 to close at $0.19, a downside of -40.91 percent. An average of 2,120,220 shares of common stock have been traded in the last five days. There was a fall of -$0.1390 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 826,605 shares traded, while the 50-day average volume stands at 622,164.
MTNB stock has decreased by -47.86% in the last month. The company shares reached their 1-month lowest point of $0.1103 on 08/10/23. With the stock rallying to its 52-week high on 04/20/23, shares of the company touched a low of $0.32 and a high of $0.90 in 52 weeks. It has reached a new high 13 times so far this year and lost -61.00% or -$0.3050 in price. In spite of this, the price is down -78.33% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Matinas BioPharma Holdings Inc. (MTNB) stock’s beta is 1.95. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.68, the price-to-book (PB) ratio at 1.30.
Financial Health
The quick ratio of Matinas BioPharma Holdings Inc. for the three months ended June 29 was 14.90, and the current ratio was 14.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Matinas BioPharma Holdings Inc.’s EBITDA margin for the year ending June 29 is -743.16%. Its gross profit as reported stood at $27.78 million compared to revenue of $3.19 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Matinas BioPharma Holdings Inc.’s return on assets was -44.90%.
Earnings Surprise
For the three-month period that ended June 29, Matinas BioPharma Holdings Inc. had $12.77 million in cash. The company posted a net income of -$6.06 million in the quarter, while revenues of -$5.51 million were grew 2.31%. The analyst consensus anticipated Matinas BioPharma Holdings Inc.’s latest quarter earnings to come in at -$0.03 per share, but it turned out to be -$0.03, a 0.00% surprise. For the quarter, EBITDA amounted to -$5.9 million. Shareholders own equity worth $217.26 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Matinas BioPharma Holdings Inc. (MTNB) price momentum. RSI 9-day as of the close on 10 August was 12.95%, suggesting the stock is oversold, with historical volatility in this time frame at 250.52%.
As of today, MTNB’s price is $0.3064 -41.62% or -$0.1390 from its 5-day moving average. MTNB is currently trading -47.67% lower than its 20-day SMA and -49.87% lower than its 100-day SMA. However, the stock’s current price level is -51.26% below the SMA50 and -77.16% below the SMA200.
The stochastic %K and %D were 15.80% and 13.88%, respectively, and the average true range (ATR) was 0.0501. With the 14-day stochastic at 27.35% and the average true range at 0.0436, the RSI (14) stands at 20.39%. The stock has reached -0.0374 on the 9-day MACD Oscillator while the 14-day reading was at -0.0608.
Analyst Ratings
Piper Sandler downgraded Matinas BioPharma Holdings Inc. (AMEX: MTNB) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for Matinas BioPharma Holdings Inc. (MTNB) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell MTNB, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is MTNB’s price target for the next 12 months?
Analysts predict a range of price targets between $1.50 and $3.00, with a median target of $2.25. Taking a look at these predictions, the average price target given by analysts for Matinas BioPharma Holdings Inc. (MTNB) stock is $2.25.
